Structural Basis for Xenosiderophore Utilization by the Human Pathogen Staphylococcus aureus
- 30 May 2017
- journal article
- research article
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 3 (7) , 542-553
Abstract
Staphylococcus aureus produces a cocktail of metallophores (staphylopine, staphyloferrin A, and staphyloferrin B) to scavenge transition metals during infection of a host. In addition, S. aureus displays the extracellular surface lipoproteins FhuD1 and FhuD2 along with the ABC transporter complex FhuCBG to facilitate the use of hydroxamate xenosiderophores such as desferrioxamine B (DFOB) for iron acquisition. DFOB is used as a chelation therapy to treat human iron overload diseases and has been linked to an increased risk of S. aureus infections. We used a panel of synthetic DFOB analogs and a FhuD2-selective trihydroxamate sideromycin to probe xenosiderophore utilization in S. aureus and establish structure–activity relationships for Fe(III) binding, FhuD2 binding, S. aureus growth promotion, and competition for S. aureus cell entry. Fe(III) binding assays and FhuD2 intrinsic fluorescence quenching experiments revealed that diverse chemical modifications of the terminal ends of linear ferrioxamine siderophores influences Fe(III) affinity but not FhuD2 binding. Siderophore–sideromycin competition assays and xenosiderophore growth promotion assays revealed that S. aureus SG511 and ATCC 11632 can distinguish between competing siderophores based exclusively on net charge of the siderophore–Fe(III) complex. Our work provides a roadmap for tuning hydroxamate xenosiderophore scaffolds to suppress (net negative charge) or enhance (net positive or neutral charge) uptake by S. aureus for applications in metal chelation therapy and siderophore-mediated antibiotic delivery, respectively.Keywords
Funding Information
- Division of Chemistry (1654611)
- Oak Ridge Associated Universities (FY2014-215)
This publication has 95 references indexed in Scilit:
- Exploiting bacterial DNA gyrase as a drug target: current state and perspectivesApplied Microbiology and Biotechnology, 2011
- Staphylococcus aureus Transporters Hts, Sir, and Sst Capture Iron Liberated from Human Transferrin by Staphyloferrin A, Staphyloferrin B, and Catecholamine Stress Hormones, Respectively, and Contribute to VirulenceInfection and Immunity, 2011
- Specificity of Staphyloferrin B Recognition by the SirA Receptor from Staphylococcus aureusJournal of Biological Chemistry, 2010
- The Staphylococcus aureus Siderophore Receptor HtsA Undergoes Localized Conformational Changes to Enclose Staphyloferrin A in an Arginine-rich Binding PocketJournal of Biological Chemistry, 2010
- Siderophores from Neighboring Organisms Promote the Growth of Uncultured BacteriaChemistry & Biology, 2010
- Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus StrainsAntimicrobial Agents and Chemotherapy, 2009
- Siderophore-Mediated Iron Acquisition Systems in Bacillus cereus: Identification of Receptors for Anthrax Virulence-Associated Petrobactin,Biochemistry, 2009
- Is drug release necessary for antimicrobial activity of siderophore-drug conjugates? Syntheses and biological studies of the naturally occurring salmycin “Trojan Horse” antibiotics and synthetic desferridanoxamine-antibiotic conjugatesBioMetals, 2009
- Sideromycins: tools and antibioticsBioMetals, 2009
- Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug BindingAntimicrobial Agents and Chemotherapy, 2008